• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login

    Investing News NetworkYour trusted source for investing success

    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Biotech Market
    Biotech News
    Biotech Stocks
    • Biotech Market
    • Biotech News
    • Biotech Stocks

    Bristol Myers Squibb Donates $11 Million to Advance Health Equity

    Investing News Network
    Feb. 23, 2021 07:59PM PST
    Biotech Investing
    Delivering on commitments announced in 2020, BMS donates funds to 56 nonprofits serving medically underserved populations across the U.S. Bristol Myers Squibb today announced it has donated a total of $11 million to 56 nonprofit organizations focused on advancing health equity in the United States. These organizations will deliver programs to improve access to high-quality care as well as increase disease awareness ...
     

       Delivering on commitments announced in 2020, BMS donates funds to 56 nonprofits serving medically underserved populations across the U.S.   

     

      Bristol Myers Squibb (NYSE: BMY) today announced it has donated a total of $11 million to 56 nonprofit organizations focused on advancing health equity in the United States. These organizations will deliver programs to improve access to high-quality care as well as increase disease awareness and education in racially and ethnically diverse and medically underserved communities, and to improve diversity in clinical research.

     

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210224005284/en/  

     
     BMS Commitment To Advance Health Equity (Graphic: Business Wire)

    BMS Commitment To Advance Health Equity (Graphic: Business Wire)

     

     

    The donations, awarded in response to a special request for proposals, leverage $11 million of the $150 million pledged by the company in August 2020 to advance diversity, inclusion and health equity.

     

    "We are realizing our vision to transform patients' lives through science as we build upon our company's strong foundation of addressing global health disparities to become one of the world's most inclusive biopharma companies," said Adam Lenkowsky, Senior Vice President, General Manager of U.S. Commercial at Bristol Myers Squibb. "We understand that the need has never been more urgent, and we have made it a priority to focus our capabilities and resources to eliminate the barriers to accessing high-quality care that exist for underserved and vulnerable populations."

     

    He added, "In line with this priority, we have chosen organizations that have demonstrated a track record of innovative and effective work in health equity and strong ties to patients and communities. Individually, each is directing its expertise to address the root causes of inequities and to create sustainable solutions. Collectively, this funding initiative will effect change within the health care ecosystem to positively impact the equitable delivery of quality healthcare."

     

    The grant recipients include U.S.-based patient advocacy and community-based organizations, health equity coalitions, medical societies, nonprofit healthcare institutions and others to fuel their health equity initiatives that support diverse populations including Black/African Americans, Latinx/Hispanic Americans, Asians, American Indian/Alaska Natives, Women, LGBTQ+, people with disabilities and more. The full list can be viewed above.

     

    The donations will fund development and delivery of innovative health equity programs in areas of high unmet need within therapeutic areas such as Oncology, Hematology, Immunology and Cardiovascular Disease. The organizations will track metrics, including the number of individuals served, demographics about the targeted population and others that demonstrate the positive impact of the donation. Evaluation reports will be provided every six months, and a final impact report issued at the program conclusion.

     

      Commitment to Health Equity by Bristol Myers Squibb and the Bristol Myers Squibb Foundation  

     

    Recognizing the need to better serve and collaborate with an increasingly diverse U.S. population and underserved communities around the world, Bristol Myers Squibb and the Bristol Myers Squibb Foundation are taking concrete steps to accelerate their respective commitments to health equity and diversity and inclusion. Bristol Myers Squibb commits to providing an additional $50 million in health equity and disease awareness and education focused grants by 2025, increasing awareness of its patient support and affordability program in communities of need, and spending $1 billion with diverse suppliers by 2025. The Bristol Myers Squibb Foundation, an independent nonprofit organization, commits to delivering a new clinical trial career development program for 250 new clinical investigators who are racially and ethnically diverse or who are committed to serving diverse and medically underserved communities, and to mentoring 250 racially and ethnically diverse medical school students to build a career pipeline with the goal of increasing diversity of participants in clinical research.

     

    For more information on the Bristol Myers Squibb and Bristol Myers Squibb Foundation commitments to health equity and diversity and inclusion, visit BMS.com .

     

      About Bristol Myers Squibb  

     

    Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , Twitter , YouTube , Facebook , and Instagram .

     

    corporatefinancial_news

     

      

     

      View source version on businesswire.com:    https://www.businesswire.com/news/home/20210224005284/en/   

     

      Bristol Myers Squibb  
    Media:
    media@bms.com  

     

    News Provided by Business Wire via QuoteMedia

    The Conversation (0)

    Latest News

    Quarterly Activities/Appendix 4C Cash Flow Report

    Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart

    RAD receives IND approval from US FDA for Betabart (RV-01)

    Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

    More News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Biotech Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×